Patient characteristics
| Patient . | Age/sex . | Diagnosis . | Cytogenetics . | % CD33 expression . | Previous therapy . |
|---|---|---|---|---|---|
| 1 | 74/F | AML, M2, rel | + 8 | 86 | IDR/Ara-C × 2, HiDAC |
| 2 | 54/F | AML, M0, rel | inv (3) | 37 | IDR/Ara-C × 2, AlloBMT, Mito/VP-16 |
| 3 | 64/M | AML, M2, rel | NE | 68 | IDR/Ara-C, IL-2, HiDAC |
| 4 | 67/F | AML, M2, rel | Normal | 83 | IDR/Ara-C, MEC |
| 5 | 70/F | AML, M2, ref | − 5, − 7, + 8, + 11, − 18, − 20, del (20) | 48 | IDR/Ara-C × 2 |
| 6 | 66/M | AML, M6, rel | del (9) | 75 | IDR/Ara-C, Mito/VP-16 |
| 7 | 17/M | AML, M2, ref | − 7 | 57 | IDR/Ara-C, HiDAC |
| 8 | 68/F | AML, M2, rel | − 7, t(2;3) | 84 | Mito/Ara-C, HiDAC, Mito/VP-16, 2-CDA |
| 9 | 30/M | AML, M2, rel | Normal | 75 | IDR/Ara-C, Mito/VP-16, Ara-C, AuPBPCT |
| 10 | 50/F | AML, M2, rel | Normal | 40 | Mito/Ara-C, HiDAC, AuPBPCT |
| 11 | 62/M | AML, M2, rel | + 21 | 48 | IDR/Ara-C, HiDAC × 2, Mito/VP-16, HiDAC × 4 |
| 12 | 57/F | AML, M2, rel | Normal | 63 | HiDAC/IDR, HiDAC/VP-16, HuM195 |
| 13 | 45/M | AML, M2, rel | + 8 | 65 | HiDAC/IDR, HiDAC/VP-16, AlloBMT |
| 14 | 42/F | AML, M2, ref | − 4, del(5), del(7), add (17), − 20 | 92 | HiDAC/IDR, VP-16/Cy |
| 15 | 49/F | AML, M2, rel | Normal | 99 | DNR/Ara-C, HiDAC/Mito, HiDAC × 2 |
| 16 | 19/F | AML, M1, rel | t(9;11) | 97 | IDR/Ara-C, HiDAC/DNR, HiDAC × 2, Mito/VP-16, Gemcitabine |
| 17 | 63/F | CMMOL, rel | Normal | 96 | IDR/Ara-C, MEC |
| 18 | 49/M | AML, M3, rel | dup(1), t(15;17) | 73 | ATRA, Ara-C/VP-16, HiDAC × 2, ATRA/Dox, ATO × 4 |
| Patient . | Age/sex . | Diagnosis . | Cytogenetics . | % CD33 expression . | Previous therapy . |
|---|---|---|---|---|---|
| 1 | 74/F | AML, M2, rel | + 8 | 86 | IDR/Ara-C × 2, HiDAC |
| 2 | 54/F | AML, M0, rel | inv (3) | 37 | IDR/Ara-C × 2, AlloBMT, Mito/VP-16 |
| 3 | 64/M | AML, M2, rel | NE | 68 | IDR/Ara-C, IL-2, HiDAC |
| 4 | 67/F | AML, M2, rel | Normal | 83 | IDR/Ara-C, MEC |
| 5 | 70/F | AML, M2, ref | − 5, − 7, + 8, + 11, − 18, − 20, del (20) | 48 | IDR/Ara-C × 2 |
| 6 | 66/M | AML, M6, rel | del (9) | 75 | IDR/Ara-C, Mito/VP-16 |
| 7 | 17/M | AML, M2, ref | − 7 | 57 | IDR/Ara-C, HiDAC |
| 8 | 68/F | AML, M2, rel | − 7, t(2;3) | 84 | Mito/Ara-C, HiDAC, Mito/VP-16, 2-CDA |
| 9 | 30/M | AML, M2, rel | Normal | 75 | IDR/Ara-C, Mito/VP-16, Ara-C, AuPBPCT |
| 10 | 50/F | AML, M2, rel | Normal | 40 | Mito/Ara-C, HiDAC, AuPBPCT |
| 11 | 62/M | AML, M2, rel | + 21 | 48 | IDR/Ara-C, HiDAC × 2, Mito/VP-16, HiDAC × 4 |
| 12 | 57/F | AML, M2, rel | Normal | 63 | HiDAC/IDR, HiDAC/VP-16, HuM195 |
| 13 | 45/M | AML, M2, rel | + 8 | 65 | HiDAC/IDR, HiDAC/VP-16, AlloBMT |
| 14 | 42/F | AML, M2, ref | − 4, del(5), del(7), add (17), − 20 | 92 | HiDAC/IDR, VP-16/Cy |
| 15 | 49/F | AML, M2, rel | Normal | 99 | DNR/Ara-C, HiDAC/Mito, HiDAC × 2 |
| 16 | 19/F | AML, M1, rel | t(9;11) | 97 | IDR/Ara-C, HiDAC/DNR, HiDAC × 2, Mito/VP-16, Gemcitabine |
| 17 | 63/F | CMMOL, rel | Normal | 96 | IDR/Ara-C, MEC |
| 18 | 49/M | AML, M3, rel | dup(1), t(15;17) | 73 | ATRA, Ara-C/VP-16, HiDAC × 2, ATRA/Dox, ATO × 4 |
Rel indicates relapse; ref, refractory; Ara-C, cytarabine; HiDAC, high-dose cytarabine; AlloBMT, allogeneic bone marrow transplantation; Mito, mitoxantrone; VP-16, etoposide; IL-2, interleukin-2; MEC, mitoxantrone, etoposide, and cytarabine; 2-CDA, cladribine; AuPBPCT, autologous peripheral blood progenitor cell transplantation; Cy, cyclophosphamide; DNR, daunorubicin; ATRA, all-transretinoic acid; Dox, doxorubicin; ATO, arsenic trioxide; NE, not evaluable.